Agomelatine

First-in-class melatonergic antidepressant (MT1/MT2 agonist + 5-HT2C antagonist) — sleep-promoting at night, mood-bright + anxiolytic during the day, no SSRI sexual side effects, no benzo dependence, no next-day sedation. EU-approved 2009; FDA-rejected (Novartis pulled the NDA in 2011 after failed Phase 3 + liver-toxicity signal). Clinical efficacy real but modest — Cipriani 2018's 21-antidepressant network meta-analysis ranks it among only three drugs with both higher-than-average efficacy AND higher-than-average acceptability, but unpublished-trial-corrected meta-analyses suggest it may be barely superior to placebo. For Dylan: WATCH-LIST. The mechanism is the right shape for late-chronotype migration + mood support, but the LFT-monitoring requirement, US-access friction, and publication-bias-clouded efficacy push it behind cheaper-cleaner options (low-dose melatonin + tryptophan + behavioral phase advance).

Agomelatine is a naphthalene analog of melatonin with a uniquely dual receptor profile that's unlike any other approved antidepressant.

Melatonergic side (the sleep + circadian leg):

• Full agonist at MT1 (Ki = 0.1 nM) and MT2 (Ki = 0.12 nM) per Audinot et al. 2003 and Conway et al. 2000 (the canonical Servier-lineage receptor-binding characterization papers using human-cloned MT1/MT2 receptors). Both Ki values are in the sub-nanomolar to low-nanomolar range, comparable to or slightly higher affinity than native melatonin itself (melatonin Ki at MT1 ≈ 0.08 nM, at MT2 ≈ 0.38 nM, depending on assay system) — meaning agomelatine binds and activates these receptors with potency essentially equivalent to the endogenous ligand.
• MT1 (Ki = 0.1 nM): mediates the sleep-promoting / wake-suppressing arm of melatonin signaling. High MT1 expression in the suprachiasmatic nucleus (SCN), pars tuberalis of the pituitary, and various forebrain regions. MT1 activation acutely suppresses SCN neuronal firing → contributes to the sleep-onset signal.
• MT2 (Ki = 0.12 nM): mediates the phase-shifting arm — the receptor that lets bright-light or melatonin pulses move the circadian clock around the 24-hour wheel via the SCN. MT2 activation produces phase advances (when timed appropriately relative to the user's circadian phase) and consolidates slow-wave sleep. MT2 is the primary receptor through which agomelatine exerts its chronotype-migration effect — the mechanistic basis for the Inoue 2022 DSPD trial signal and the rationale for Dylan's hypothetical late-chronotype use case.
• Selectivity: Agomelatine has essentially no affinity for MT3 (which is now reclassified as quinone reductase 2 / QR2), making it more cleanly MT1/MT2-selective than some natural melatonin metabolites. The MT3 inactivity rules out potential off-target oxidative-stress modulation that could otherwise complicate the safety profile.
• Functional efficacy at MT1/MT2: Agomelatine is a full agonist (Emax ≈ 100% of melatonin's max response) at both receptors — meaning it produces the maximum possible receptor activation, not partial activation. This is unusual; many melatonergic candidates are partial agonists at one or both subtypes (e.g., ramelteon is a full MT1 agonist but partial MT2 agonist).
• Half-life is ~1-2 hr (much shorter than therapeutic melatonin formulations) — so the melatonergic signal is concentrated in the first few hours after dosing, mimicking endogenous evening melatonin onset. The short t½ is a feature, not a bug: it confines the MT1/MT2 activation to the sleep-onset / early-night window when these signals are physiologically appropriate, avoiding next-morning carryover.
• Net circadian effect: resynchronizes / phase-advances disturbed sleep-wake cycles, consolidates slow-wave sleep, preserves REM (unlike most sedating antidepressants), no next-morning grogginess

Serotonergic side (the mood + anxiolytic leg):

• Selective 5-HT2C antagonist (Ki ≈ 270 nM) — no meaningful binding to 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3, 5-HT6, 5-HT7, alpha/beta adrenergic, histaminergic, muscarinic, dopaminergic, or GABAergic receptors
• 5-HT2C receptors normally inhibit mesocortical/mesolimbic dopaminergic + noradrenergic neurons. Blocking them disinhibits these systems → indirect rise in DA and NE in the frontal cortex specifically (this is the regional specificity people miss — agomelatine doesn't dump DA across the brain like a stimulant; it lifts the brake selectively in PFC)
• This is the mechanistic basis for the antidepressant + anhedonia + motivation effect — same final pathway as bupropion's NDRI action, achieved by a completely different upstream lever
• 5-HT2C blockade also has direct anxiolytic effects in animal models, consistent with the GAD efficacy data

Why the dual mechanism makes physiological sense:

• Major depression is associated with circadian disruption — phase-delay of melatonin secretion, disturbed sleep architecture, blunted cortisol rhythm
• Agomelatine attacks this from both sides: the MT1/MT2 leg restores the circadian signal, the 5-HT2C leg lifts the cortical mood/motivation deficit
• Chronic dosing increases hippocampal BDNF (rodent + some human imaging data) — neuroplasticity effect overlaps with SSRIs

What agomelatine does NOT do:

• No serotonin reuptake inhibition (so no SSRI-style serotonergic side effects: sexual dysfunction, GI distress, emotional blunting, discontinuation syndrome)
• No norepinephrine reuptake inhibition (no stim-flavored agitation profile)
• No histaminergic blockade (so no antihistamine-style sedation hangover, weight gain, brain-fog typical of mirtazapine/trazodone)
• No anticholinergic activity
• No GABAergic activity (no benzo-like dependence/tolerance)